This partnership will combine both PharmaLex and Volv’s respective capabilities. Volv uses advanced predictive technologies, unassisted machine learning, artificial intelligence paradigms and web-scale technologies to develop products and services which support a number of key areas. These include supporting the monitoring of adverse events that are recorded on web forums and public social media channels, regulatory intelligence platforms, patient identification for rare diseases and their related services, as well as market access intelligence. Initially focusing on pharmacovigilance services, these added technologies will allow PharmaLex to provide its clients with an extra layer of innovative safety monitoring, ensuring all adverse events, recorded both officially and online, are formally recorded and analyzed.

 

“We are delighted to be working with PharmaLex on the development of their pharmacovigilance solutions”, explained Christopher Rudolf, founder and CEO of Volv. “Our innovative technology has an open design and intuitive interface, ensuring it can easily integrate into existing PV platforms.”

 

Dr. Thomas Dobmeyer, CEO PharmaLex added: “The increasing volume of relevant literature in the medico-scientific domain is a challenge. Embedded artificial intelligence and cognitive computing technology allows for increased efficiency, especially in the area of drug adverse event monitoring.”